Company: BGLC
Filing Date: 2025-11-14
Form Type: PRE 14A
Source: 0001477932-25-008317
Chunk: 18

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: PRE 14A
Chunk 18
---
      1 |    3 |   |          0 |               0 |
| South Asian                                                      |     |      0 |    0 |   |          0 |               0 |
| Hispanic or Latinx                                               |     |      0 |    0 |   |          0 |               0 |
| Native Hawaiian or Pacific Islander                              |     |      0 |    0 |   |          0 |               0 |
| White                                                            |     |      0 |    0 |   |          0 |               0 |
| Two or More Races or Ethnicities                                 |     |      0 |    0 |   |          0 |               0 |
| LGBTQ+                                                           |     |        |      |   |          0 |                 |
| Did Not Disclose Demographic Background                          |     |        |      |   |          0 |                 |

Vote Required

Directors are elected by a plurality of the votes cast, with the four nominees obtaining the greatest number of affirmative votes being elected as Directors, even if less than a majority. As a result, abstentions and broker non-votes will have no effect on the vote outcome.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" EACH OF THE NOMINEES FOR DIRECTOR.

| 14 |

<div align='center'>PROPOSAL 2:

APPROVAL OF THE 2025 EQUITY INCENTIVE PLAN</div>

Background and Overview

The Compensation Committee of the Board has recommended that the Company should establish and maintain an equity incentive plan pursuant to which the Company may offer selected officers, directors (including independent directors), employees of and consultants to the Company and its subsidiaries the opportunity to acquire or increase equity ownership in the Company.

On November [*], 2025, the Board adopted, subject to shareholders’ approval, the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan (the “Incentive Plan”). The Incentive Plan is designed to enable the flexibility to grant equity awards to our key management employees, directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. If the Incentive Plan is not approved by the Shareholders, the Incentive Plan will not be in effect.

Summary of the Provisions of the Incent